+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Pulmonary Hypertension KOL Interview - Germany

  • PDF Icon


  • 12 Pages
  • March 2024
  • Region: Germany
  • Citeline
  • ID: 5642902
This interview with a Germany-based key opinion leader (KOL) provides insights into current prescribing habits on- and off-label in WHO groups 1-5, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for pulmonary hypertension. Key assets highlighted include Uptravi, Opsumit, Tyvaso, Remodulin (and Remunity), Adcirca, INOpulse, and sotatercept.